-
公开(公告)号：US06919311B2
公开(公告)日：2005-07-19
申请号：US09831679
申请日：2001-05-10
Applicant: Petrus Johannes Lenting , Jan Aart Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
Inventor： Petrus Johannes Lenting , Jan Aart Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
IPC: A61K38/00 , A61K38/37 , C07K14/705 , C07K14/755 , C12N15/12 , A61K38/01 , C12Q1/56
CPC classification number: C07K14/755 , A61K38/00 , A61K38/37 , C07K14/705 , A61K2300/00
Abstract: Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.
Abstract translation: 具有FVIII：C活性的因子VIII多肽，其含有因子VIII轻链序列的A3和/或C1和/或C2结构域的修饰，其特征在于与低密度脂蛋白受体蛋白的结合亲和力，以及生产方法 一样。
-
2.发明授权Antibodies specific for a haemostatic protein their use for isolating protein, haemostatic compositions devoid of proteolytic cleavage products of the protein 失效用于分离蛋白质的止血蛋白质的特异性抗体，没有蛋白质的蛋白水解切割产物的止血组合物
公开(公告)号：US5932706A
公开(公告)日：1999-08-03
申请号：US797842
申请日：1997-02-10
Applicant: Koenraad Mertens , Jan Aart van Mourik
Inventor： Koenraad Mertens , Jan Aart van Mourik
IPC: G01N33/53 , A61K38/00 , A61K38/36 , A61K38/43 , A61K39/395 , A61P7/00 , A61P7/04 , B01J20/281 , C07K1/00 , C07K1/22 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/745 , C07K14/755 , C07K16/36 , C12N9/64 , C12N15/02 , C12P21/08 , G01N30/88
CPC classification number: C12N9/6481 , C07K14/745 , C07K14/755 , C07K16/36 , A61K38/00
Abstract: A method for the generation of Ca++ independent antibodies against blood coagulation factors is described wherein an antibody selection strategy based upon small peptides comprising target sequences for limited proteolysis is employed. These antibodies which distinguish between intact and cleaved species of haemostatic protein provide novel tools for the isolation of intact haemostatic proteins.
Abstract translation: 描述了一种用于产生针对凝血因子的Ca ++独立抗体的方法，其中采用基于包含有限蛋白水解的靶序列的小肽的抗体选择策略。 这些区分完整和切割的止血蛋白物质的抗体为分离完整的止血蛋白提供了新的工具。
-
Patent Agency Ranking
公开(公告)号：US08546332B2
公开(公告)日：2013-10-01
申请号：US12388665
申请日：2009-02-19
Applicant: Petrus Johannes Lenting , Jan Aart Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
Inventor： Petrus Johannes Lenting , Jan Aart Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
CPC classification number: C07K14/755 , A61K38/00 , A61K38/37 , C07K14/705 , A61K2300/00
Abstract: Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.
-
公开(公告)号：US07544660B2
公开(公告)日：2009-06-09
申请号：US10986281
申请日：2004-11-12
Applicant: Petrus Johannes Lenting , Jan Aart Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
Inventor： Petrus Johannes Lenting , Jan Aart Van Mourik , Koenraad Mertens , Hans Pannekoek , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger
CPC classification number: C07K14/755 , A61K38/00 , A61K38/37 , C07K14/705 , A61K2300/00
Abstract: Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.
Abstract translation: 具有FVIII：C活性的因子VIII多肽，其含有因子VIII轻链序列的A3和/或C1和/或C2结构域的修饰，其特征在于与低密度脂蛋白受体蛋白的结合亲和力，以及生产方法 一样。
-
公开(公告)号：US20110118188A1
公开(公告)日：2011-05-19
申请号：US12388665
申请日：2009-02-19
Applicant: PETRUS JOHANNES LENTING , JAN AART VAN MOURIK , KOENRAAD MERTENS , HANS PANNEKOEK , PETER TURECEK , HANS-PETER SCHWARZ , FRIEDRICH SCHEIFLINGER
Inventor： PETRUS JOHANNES LENTING , JAN AART VAN MOURIK , KOENRAAD MERTENS , HANS PANNEKOEK , PETER TURECEK , HANS-PETER SCHWARZ , FRIEDRICH SCHEIFLINGER
IPC: A61K38/37 , C07K14/755 , A61P7/00
CPC classification number: C07K14/755 , A61K38/00 , A61K38/37 , C07K14/705 , A61K2300/00
Abstract: Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.
Abstract translation: 具有FVIII：C活性的因子VIII多肽，其含有因子VIII轻链序列的A3和/或C1和/或C2结构域的修饰，其特征在于与低密度脂蛋白受体蛋白的结合亲和力，以及生产方法 一样。
-
6.再颁专利Antibodies specific for a haemostatic protein, their use for isolating protein, haemostatic compositions devoid of proteolytic cleavage products of the protein 有权针对止血蛋白的特异性抗体，其用于分离蛋白质的用途，不含有蛋白质的蛋白水解切割产物的止血组合物公开(公告)号：USRE38202E1
公开(公告)日：2003-07-22
申请号：US09618592
申请日：2000-07-17
Applicant: Koenraad Mertens , Jan Aart van Mourik
Inventor： Koenraad Mertens , Jan Aart van Mourik
IPC: A61K39395
CPC classification number: C12N9/6481 , A61K38/00 , C07K14/745 , C07K14/755 , C07K16/36
Abstract: A method for the generation of Ca++ independent antibodies against blood coagulation factors is described wherein an antibody selection strategy based upon small peptides comprising target sequences for limited proteolysis is employed. These antibodies which distinguish between intact and cleaved species of haemostatic protein provide novel tools for the isolation of intact haemostatic proteins.
Abstract translation: 描述了一种用于产生针对凝血因子的Ca ++独立抗体的方法，其中采用基于包含有限蛋白水解的靶序列的小肽的抗体选择策略。 这些区分完整和切割的止血蛋白物质的抗体为分离完整的止血蛋白提供了新的工具。
-
7.发明授权Method and means for detecting and treating disorders in the blood coagulation cascade 失效检测和治疗血液凝固级联障碍的方法和手段
公开(公告)号：US6083905A
公开(公告)日：2000-07-04
申请号：US722240
申请日：1997-01-22
Applicant: Johannes Jacobus Voorberg , Jan Aart van Mourik , Koenraad Mertens
Inventor： Johannes Jacobus Voorberg , Jan Aart van Mourik , Koenraad Mertens
IPC: G01N33/86 , A61K38/00 , A61K38/36 , A61K38/37 , A61K38/43 , A61K48/00 , A61P7/02 , C07K14/745 , C07K14/755 , C12N9/99 , C12N15/09 , C12Q1/56 , C12Q1/68 , A01N37/18 , A61K35/14
CPC classification number: C07K14/745 , C07K14/755 , C12Q1/6883 , A61K38/00 , C12Q2600/156 , Y10S514/802 , Y10S514/822
Abstract: This invention relates to the diagnosis of congenital defects in the anticoagulant protein C system. Methods that are disclosed are based on the detection of mutations at the cleavage sites of coagulation factors that are under control of activated protein C (APC). Diagnostic tests include analysis of the APC-cleavage sites of factor V and factor VIII, by using specific primers to amplify selectively from RNA, cDNA derived from RNA or chromosomal DNA, parts of factor V and factor VIII that contain cleavage sites for APC. Methods that monitor the presence of mutations at the cleavage sites for APC and their utility in the diagnosis of thrombo-embolic disease are disclosed. The invention further discloses methods for correcting the defects detected according to the invention, as well as novel therapeutic agents which can be used in the treatment of bleeding disorders, which agents are based on the "defective" Factor V and Factor VIII proteins leading to the thrombotic disorders described hereinabove.
Abstract translation: PCT No.PCT / NL95 / 00149 Sec。 371日期1997年1月22日 102（e）日期1997年1月22日PCT 1995年4月21日PCT PCT。 第WO95 / 29259号公报 日期1995年11月2日本发明涉及抗凝蛋白C系统中先天性缺陷的诊断。 所公开的方法基于在活化蛋白C（APC）控制下的凝血因子的切割位点处的突变的检测。 诊断测试包括通过使用特异性引物从RNA，RNA或染色体DNA衍生的cDNA，包含APC切割位点的因子V和因子VIII的部分选择性地扩增，分析因子V和因子VIII的APC-切割位点。 公开了监测APC切割位点突变存在的方法及其在血栓栓塞性疾病诊断中的应用。 本发明还公开了用于校正根据本发明检测到的缺陷的方法，以及可用于治疗出血性疾病的新型治疗剂，所述治疗剂基于导致其的“缺陷”因子V和因子VIII蛋白 上文描述的血栓形成障碍。
-
-
-
-
-
-
Search Results
7
records
(took 0.012 seconds)
